Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.

Scientific reports - 10 Feb 2020

Hassan Nourhan, Rutsch Niklas, Győrffy Balázs, Espinoza-Sánchez Nancy Adriana, Götte Martin

Abstract excerpt

In several carcinomas, the SET Domain Containing 3, Actin Histidine Methyltransferase (SETD3) is associated with oncogenesis. However, there is little knowledge about the role of SETD3 in the progression and prognosis of breast cancer. In this study, we first analyzed the prognostic value of SETD3 in breast cancer patients using the database of the public Kaplan-Meier plotter. Moreover, in vitro assays were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Methyltransferases

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 32042016
DOI: 10.1038/s41598-020-59057-5
PMCID: PMC7010743

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.PMID 32042016Read ↗

Prognostic and Immunological Characterization of NSD3 Evaluated Through an Integrative Pan-Cancer AnalysisSemantic proximity Read ↗

Prognostic prediction and expression validation of NSD3 in pan-cancer analysesSemantic proximity Read ↗

Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironmentSemantic proximity Read ↗

SETD3 is a positive regulator of DNA-damage-induced apoptosisSemantic proximity Read ↗

Metastatic function of METTL18 in breast cancer via actin methylation and SrcSemantic proximity Read ↗

NSD3, a New SET Domain-Containing Gene, Maps to 8p12 and Is Amplified in Human Breast Cancer Cell LinesSemantic proximity Read ↗

HDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4.Semantic proximity Read ↗

The Role of the Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 In Breast Cancer PathophysiologySemantic proximity Read ↗

Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.Semantic proximity Read ↗

The chromatin remodeler SMARCD3 regulates cell cycle progression and its expression predicts survival outcome in ER+ breast cancerSemantic proximity Read ↗

DEDD Interacts with PI3KC3 to Activate Autophagy and Attenuate Epithelial–Mesenchymal Transition in Human Breast CancerSemantic proximity Read ↗

SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.